Last reviewed · How we verify
Ethinone (ETHISTERONE)
Ethinone (generic name: ETHISTERONE) is a ethisterone drug. It is currently in Phase 3 development.
Ethinone works by binding to sex hormone-binding globulin, affecting the levels of sex hormones in the body.
Ethinone, also known as ethisterone, is a small molecule drug in the ethisterone class that targets sex hormone-binding globulin. It is not FDA-approved for any indications, and its commercial status, generic availability, and patent status are unknown. Ethinone works by binding to sex hormone-binding globulin, which affects the levels of sex hormones in the body. As a result, it may be used to treat conditions related to hormonal imbalances. However, due to its unknown status, its use and safety considerations are not well established.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETHISTERONE |
|---|---|
| Drug class | ethisterone |
| Target | Sex hormone-binding globulin, Glucocorticoid receptor, Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Think of sex hormone-binding globulin like a container that holds onto sex hormones in the body. Ethinone is like a key that fits into this container, changing how many sex hormones are available. This can affect how the body works, especially for people with hormonal imbalances.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinone CI brief — competitive landscape report
- Ethinone updates RSS · CI watch RSS
Frequently asked questions about Ethinone
What is Ethinone?
How does Ethinone work?
What is the generic name of Ethinone?
What drug class is Ethinone in?
What development phase is Ethinone in?
What does Ethinone target?
Related
- Drug class: All ethisterone drugs
- Target: All drugs targeting Sex hormone-binding globulin, Glucocorticoid receptor, Androgen receptor
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing